Such a humbling and unforgettable experience to present my poster surrounded by #gyncsm giants at #ASCO23 ♥️ dreams come true when someone believes in you.
#OvarianCancer#research @NCICCR_WMB @theNCI @NCIResearchCtr
❓Are cancer CTs only for patients with good PS?
🔹Only 25.8% of 283 pivotal CTs included ECOG PS ≥2 pts.
🔸 Median enrollment was 4.3%
💡Real change needs Sponsors, IRBs/ECs, Investigators working together
👉🏻Read the full paper: https://t.co/p5Kj0bD5cY
The ESGO Council is extremely saddened to learn of the untimely death of Prof Giovanni Scambia, who was a great influence to and personal friend of many of our members. A moment of silence was held today during the Congress opening ceremony in his honour.
Prof Scambia touched the lives of countless patients, surgeons, fellows and others in the gynae oncology community.
We extend our condolences to his family and the many, many others who are mourning his passing. His memory will live on.
Huge congrats to @apolo_andrea, an incredible physician-scientist and a true leader dedicated to improve the life of bladder cancer patients 🥇
#ESMO24@myESMO@nciccr_gmb @NCICCR_MOS @NCIResearchCtr @theNCI
#ESMOGynae24: Advances over the last decade have significantly transformed the management of #GynaecologicalCancers, particularly the prevention and treatment of three main types: endometrial, cervical, and ovarian cancer. #ESMODailyReporter
📌https://t.co/yukQ1fRnmt
A study in BMJ Oncology suggests MMR-D/MSI-H urothelial cancer may confer high sensitivity to immunotherapy. This could spare patients the morbidity of radical surgery and the toxicities of chemotherapy.
@apolo_andrea@EliasChandran@GMIannantuonoMD
https://t.co/UXkRysD483
Very honoured to have had the opportunity to work on this project at the @NCIResearchCtr with such a great mentor and PI, Dr. Jung-Min Lee, and all the members of her lab ♥️ #ovariancancer needs #research 👩🔬🔬🧪
#ChatGPT-4 & ChatGPT-3.5 are potentially powerful tools in #immunooncology, but risk of inaccurate/incomplete responses stresses the importance of expert-driven verification of outputs generated by these #AI technologies. @chfloudas@GMIannantuonoMD https://t.co/fnH9xlmRea
🔍Do Italian clinical trials report the race and ethnicity of the enrolled population?
#AIOM23@AIOMtweet
@unitorvergata
Thanks to a special friend like @SSgangaMD for his valuable contribution 💪🏻
Atezo bev and platinum based chemo regardless of PD-L1 status. Every #cervicalcancer patient deserves #ICIs. Congratulations to @AnaOaknin for those outstanding results! #BEATcc trial #esmo#plenary#gynonc